Amgen Sponsors Golden Ticket at BioLabs LA at The Lundquist Institute to Help Accelerate Life Science Startups

- Amgen (NASDAQ:AMGN) today announced a three-year, Golden Ticket sponsorship of the BioLabs LA at The Lundquist Institute (TLI) life sciences co-working space to accelerate the development of new therapies, medical devices, and diagnostics to advance and improve human health. The BioLabs at TLI shared laboratory space was created to help high-potential life science and biotech startups overcome key obstacles for many early stage organizations, including: access to laboratory infrastructure, programming, and business development mentorship.

As part of the sponsorship, Amgen will launch one "Amgen Golden Ticket" award each year for three years, providing winners with one year of lab space at BioLabs as well as additional facility benefits and connections to Amgen's scientific and business leaders.

"Recognizing the growing biotech ecosystem in Southern California , Amgen's sponsorship of the Golden Ticket with BioLabs aims to further foster early-stage life science companies right in the backyard of Amgen's headquarters," said Philip Tagari , Ph.D., vice president of Therapeutic Discovery at Amgen. "It's very rewarding to be part of the growing energy, reach, and enthusiasm of the many talented scientific entrepreneurs across the broader Los Angeles area. BioLabs is a model for how life science startups can grow and thrive in a rapidly emerging bioscience community."

"Having Amgen join BioLabs at TLI as a significant sponsor sends a clear message about how Los Angeles has progressed as a major bioscience hub and how far our shared laboratory facility has come in just over a year of operation," said Keith B. Hoffman , Ph.D., senior vice president of Business Development and Technology Transfer at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. "I'm extremely proud that we were able to bring the BioLabs organization to Los Angeles and that the BioLabs facility at TLI now houses the highest concentration of promising bioscience startups in the greater Los Angeles region. This partnership with Amgen represents another significant step in the rapid expansion and reach of the Los Angeles bioscience community within and surrounding counties in Southern California . I'm honored to add Amgen's substantial reputation and reach to our member companies already in the space, and those who will join us in the future."

"We're thrilled that Amgen has joined as our newest sponsor and look forward to working with the Amgen team to support these early-stage entrepreneurs and to help accelerate development of new therapies to improve human health," said BioLabs President & CEO Johannes Fruehauf , M.D., Ph.D. "With their deep expertise as developers of biotech-based drugs, Amgen is an ideal partner for many of BioLabs' resident companies working on promising new biopharmaceuticals."

Amgen supports life science start-ups through Golden Ticket awards and affiliated engagement in other Biotech Innovative hubs, including San Francisco , Boston and Toronto .

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen .

About The Lundquist Institute: Research with reach™
The Lundquist Institute is an engine of innovation with a global reach and a 68-year reputation of improving and saving lives. With its new medical research building, its state-of-the-art incubator, "BioLabs at The Lundquist," existing laboratory and support infrastructure, and a 15-acre tech park in the planning stages, the Lundquist Institute serves as a hub for the Los Angeles area's burgeoning biotech scene. The research institute has over 100 principal investigators (Ph.D.s, M.D.s, and M.D./Ph.D.s) working on more than 600 research studies, including therapies for numerous, and often fatal orphan diseases. Find out more at https://lundquist.org .

About BioLabs LA at The Lundquist Institute
Encompassing the entire third floor of The Lundquist Institute's new Medical Research Lab building, BioLabs LA offers shared lab facilities designed for high-potential, early-stage life since companies. BioLabs creates co-working communities that pair premium, fully equipped and supported lab and office space with unparalleled access for entrepreneurs to networking, industry partners, and capital. Find out more at https://www.biolabs.io/la .

CONTACT:

Amgen
Jessica Akopyan , (805) 447-0974, jakopyan@amgen.com (media)

The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Keith B. Hoffman , Ph.D., (310) 974-9301, keith.hoffman@lundquist.org

BioLabs LA
Gary Olsem , (310) 618-6892, gary@biolabs.io

Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-sponsors-golden-ticket-at-biolabs-la-at-the-lundquist-institute-to-help-accelerate-life-science-startups-301221617.html

SOURCE Amgen

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
  BPH Global Ltd

Notice of Extraordinary General Meeting/Proxy Form

Notice is hereby given that an Extraordinary General Meeting of Shareholders of BPH Global Limited ACN 009 104 330 will be held at 3:00pm AEST on 24 May 2024 at Suite 5, Level 12, 530 Collins Street, Melbourne VIC 3000 (Meeting).

Keep reading...Show less
Genes and chromosomes with "2024" overlay.

Biotech Market Update: Q1 2024 in Review

The first quarter of 2024 witnessed a surge in initial public offerings (IPOs) and mergers and acquisitions (M&A) within the biotech industry, signaling continued interest from investors.

AstraZeneca’s acquisition of start-up Amolyt on March 14, and its longtime biotech partner Fusion Pharmaceuticals for US$2.4 billion on March 19 marked the third acquisition of a radiopharmaceutical developer in recent months. As of writing, there have been 14 M&A deals struck in 2024, according to data from Biopharma Dive.

Investment bank Jefferies released data in early March revealing that the sector was on track to earn its highest quarterly total in three years, reflecting the cautiously optimistic outlook at this year's JPM24 conference.

Keep reading...Show less

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Planning Underway for Phase 3 Development of Tezepelumab in COPD

Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20 from 9:15-11:15 a.m. PDT .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Close up 3D rendering of DNA strands.

Biotech Stocks: 5 Biggest Companies in 2024

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in countries all around the globe.

Plus, these big-name biotech players have pipelines stuffed with potentially disruptive products — and enough revenue to recover should some of those products fail.

This means that investors can experience the excitement of biotech investing while minimizing risk. Although returns are never guaranteed, company size can insulate investors from volatility.

Keep reading...Show less
SIRONA BIOCHEM Corporate Update April 2024

SIRONA BIOCHEM Corporate Update April 2024

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") provides the following update:

Dear shareholders,

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Close of Private Placement

Sirona Biochem Announces Close of Private Placement

Vancouver, British Columbia – April 4, 2024 Sirona Biochem Corp . (TSX-V: SBM) (Frankfurt: ZSB) (" Sirona ") has closed its private placement (Private Placement") for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the "Units") at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×